Horizons in Cancer Research: Volume 51 | Agenda Bookshop Skip to content
Please note that books with a 10-20 working days delivery time may not arrive before Christmas.
Please note that books with a 10-20 working days delivery time may not arrive before Christmas.
Age Group_Uncategorized
Age Group_Uncategorized
automatic-update
B01=Hiroto S. Watanabe
Category1=Non-Fiction
Category=MJCL
COP=United States
Delivery_Delivery within 10-20 working days
Language_English
PA=In stock
Price_€100 and above
PS=Active
softlaunch

Horizons in Cancer Research: Volume 51

English

This book presents original research results on the leading edge of cancer. Topics discussed include the role of dendritic cells in the priming of cytotoxic T lymphocyte responses; current anti-cancer agents targeting apoptosis and authophagy and clues for future cancer drug discovery; the efficacy of bufadienolides and TCM preparations on in vivo and in vivo cancer models in clinical trials; the role of tetracyclic triterpenes and their glycosides in cancer prevention; adoptive cell therapy at the forefront of cancer immunotherapy; the challenges and promises of targeted chemoprevention; the physical, emotional and social challenges associated with cancer survivorship; bioinformatics tools and resources for cancer diagnosis and drug development; and the history of radical surgery for the treatment of prostate cancer. See more
Current price €214.69
Original price €225.99
Save 5%
Age Group_Uncategorizedautomatic-updateB01=Hiroto S. WatanabeCategory1=Non-FictionCategory=MJCLCOP=United StatesDelivery_Delivery within 10-20 working daysLanguage_EnglishPA=In stockPrice_€100 and abovePS=Activesoftlaunch
Delivery/Collection within 10-20 working days
Product Details
  • Weight: 602g
  • Dimensions: 180 x 260mm
  • Publication Date: 10 May 2013
  • Publisher: Nova Science Publishers Inc
  • Publication City/Country: United States
  • Language: English
  • ISBN13: 9781624173288
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept